Shingles Vaccine Shortages Result from High Demand
From The New York Times website
Shingrix, the vaccine approved last year to prevent shingles, has proved so popular that its maker, GlaxoSmithKline, has not been able to produce it quickly enough to keep up with the demand.
The vaccine is recommended for most people over 50. But many are having trouble getting it. The company says there are no manufacturing problems — it just didn’t expect so many consumers to want the vaccine.
Retiree News 
Comments are closed.